pantethine

01/01/2014 - "The efficacy of pantethine treatment on cardiovascular risk markers was investigated in a randomized, triple-blinded, placebo-controlled study, in a low to moderate cardiovascular disease (CVD) risk North American population eligible for statin therapy, using the National Cholesterol Education Program (NCEP) guidelines. "
08/01/2011 - "Safety and efficacy of a biologically active derivative of vitamin B(5) (pantethine) on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) metabolism was studied in North American subjects at conventional low to moderate cardiovascular disease (CVD) risk. "

03/01/2001 - "As a safe and effective compound of natural origin, pantethine merits broader use in the management of hyperlipidemias."
03/01/1987 - "Patients with manifest hyperlipidemia should be administered pantethine in a dose of 500 mg/day."
01/01/1987 - "A group of 18 patients with hyperlipidemias (9 M, 9 F), with an average age of 52.6 years, was submitted to pantethine parenteral treatment. "
01/01/1987 - "[Clinical use of pantethine by parenteral route in the treatment of hyperlipidemia]."
01/01/1984 - "[Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment with pantethine]."

01/01/1990 - "6. Pantethine is well tolerated by patients and has been suggested to treatment of atherosclerosis. "
01/01/1984 - "[Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment with pantethine]."
03/31/1989 - "[Pantethine, diabetes mellitus and atherosclerosis. "
01/01/1985 - "The present study indicates a favourable influence of pantethine not only on plasma but also on platelet lipids which could be of value in delaying the development of atherosclerosis in dyslipidaemic patients."
11/01/1986 - "Following a brief outline of current knowledge concerning atherosclerosis and its treatment, the authors describe the results obtained by treating with pantethine (900-1200 mg daily for 3 to 6 months) a series of 7 children and 65 adults suffering from hypercholesterolemia alone or associated with hypertriglyceridemia (types IIa and IIb of Fredrickson's classification). "

01/01/1986 - "Effectiveness of long-term treatment with pantethine in patients with dyslipidemia."
11/01/1985 - "[Use of pantethine in dyslipidemia of chronic uremic patients under dialysis treatment]."
02/01/1986 - "In the light of extensive experience with the drug, plus the results of this study, the authors conclude by stressing the importance of an effective and readily tolerated product, such as pantethine, for the treatment of dyslipidemia in patients on chronic hemodialysis."
01/01/1986 - "A one-year clinical trial with pantethine was conducted in 24 patients with established dyslipidemia of Fredrickson's types II A, II B, and IV, alone or associated with diabetes mellitus. "
02/01/1986 - "In the course of a post-marketing surveillance program on the effectiveness and tolerability of pantethine in the treatment of hyperlipidemia, the effects of the drug were explored in 31 patients with dyslipidemia undergoing chronic hemodialysis. "

01/01/2020 - "This study aimed to explore the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration (PKAN). "
01/01/2020 - "Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study."
01/01/2014 - "We here demonstrate that pantethine administration can prevent the onset of the neuromuscular phenotype in mice suggesting the possibility of experimental treatment in patients with pantothenate kinase-associated neurodegeneration. "
04/13/2010 - "Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration."
01/01/2014 - "Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model."